At the cutting edge

At the
cutting edge.

Research for life

Research
for life.

Innovation and performance

Innovation and
performance.

Latest

Whats new.

July 22nd 2024

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
July 17th 2024

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
July 12th 2024

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
more

Upcoming Events

Whats next.

August 13th 2024 - August 15th 2024

read more
September 10th 2024 - September 11th 2024

read more
September 13th 2024 - September 17th 2024

read more

Who we are

About us.

passion.

It takes a great deal of passion on the fight against cancer. We put our heart and soul into winning it.

know-how.

Our goal is to gather the strongest forces, the brightest minds and the most dedicated employees.

research.

Accurate research is the strong foundation for developing potential in effective treatment.

What is LAG3?
Lymphocyte-activation gene 3, or LAG-3 (LAG3), is a cell surface molecule with biologic effects on T cell function.
LAG3 is being used for many cancer immunotherapy treatments including Eftilagimod Alpha from Immutep.